In 2006, While working on a drug for ocular & neural cancers, Dr. Shome stumbled upon potential causes of hair fall, in the animal trial he was pursuing.
This research on Retinoblastoma conducted in collaboration with the Indian Institute of Technology, Mumbai, India (IIT) threw up an interesting phenomenon of hair loss in the animal model.
From 2006-2008, Determined pursuit of this insight leads to identification of growth factors and polypeptides possibly influencing hair growth. Signal transduction of proteins, based on animal models, were used to identify 5 naturally occurring growth factors/ polypeptides in humans.
In 2009, the First in Human trial commenced to study dose ranging and evolve optimum concentration mix to yield the best in class results.
The QR 678 ® hair formulation therapy was featured on Times Of India (India’s largest read English news daily), on first page, all editions on September 19th, 2010.
Subsequently, from 2013-2016, a Phase III clinical user trial in a large cohort of 1000 patients of both genders was completed, to test efficacy & safety of the proposed formulation. This clinical trial was published in a very reputed, top, American Journal, Journal of Cosmetic & Laser Therapy, in 2017. After 8 sessions, global photographs showed improvement from baseline for 71% patients, a decreased score for 10% patients, & no change in score for 19% patients. The findings of this study suggest that the beneficial clinical effects of this QR 678 ® hair formulation therapy are similar in men & women, across different age groups, & in patients irrespective of the presence of metabolic disorders like diabetes, hypertension, hypercholesterolemia etc.